Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

41 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Visceral Leishmaniasis in 2 Patients Treated With Lenalidomide and Dexamethasone: A Possible Correlation With Blunted Immune Response.
Hadjiaggelidou C, Vadikolia C, Verrou E, Yiannaki E, Triantafyllou T, Palaska V, Keramidioti K, Tsirou K, Papanikolaou A, Markala D, Konstantinidou P, Katodritou E. Hadjiaggelidou C, et al. Among authors: verrou e. Hemasphere. 2020 Dec 9;5(1):e506. doi: 10.1097/HS9.0000000000000506. eCollection 2021 Jan. Hemasphere. 2020. PMID: 33324952 Free PMC article. No abstract available.
Bortezomib reduces serum dickkopf-1 and receptor activator of nuclear factor-kappaB ligand concentrations and normalises indices of bone remodelling in patients with relapsed multiple myeloma.
Terpos E, Heath DJ, Rahemtulla A, Zervas K, Chantry A, Anagnostopoulos A, Pouli A, Katodritou E, Verrou E, Vervessou EC, Dimopoulos MA, Croucher PI. Terpos E, et al. Among authors: verrou e. Br J Haematol. 2006 Dec;135(5):688-92. doi: 10.1111/j.1365-2141.2006.06356.x. Br J Haematol. 2006. PMID: 17107351 Free article.
Hypochromic erythrocytes (%): a reliable marker for recognizing iron-restricted erythropoiesis and predicting response to erythropoietin in anemic patients with myeloma and lymphoma.
Katodritou E, Terpos E, Zervas K, Speletas M, Kapetanos D, Kartsios C, Verrou E, Banti A, Effraimidou S, Christakis J. Katodritou E, et al. Among authors: verrou e. Ann Hematol. 2007 May;86(5):369-76. doi: 10.1007/s00277-007-0258-x. Epub 2007 Feb 14. Ann Hematol. 2007. PMID: 17375302 Clinical Trial.
Extramedullary (EMP) relapse in unusual locations in multiple myeloma: Is there an association with precedent thalidomide administration and a correlation of special biological features with treatment and outcome?
Katodritou E, Gastari V, Verrou E, Hadjiaggelidou C, Varthaliti M, Georgiadou S, Laschos K, Xirou P, Yiannaki E, Constantinou N, Markala D, Zervas K. Katodritou E, et al. Among authors: verrou e. Leuk Res. 2009 Aug;33(8):1137-40. doi: 10.1016/j.leukres.2009.01.036. Epub 2009 Feb 27. Leuk Res. 2009. PMID: 19250676
Cystatin-C is an independent prognostic factor for survival in multiple myeloma and is reduced by bortezomib administration.
Terpos E, Katodritou E, Tsiftsakis E, Kastritis E, Christoulas D, Pouli A, Michalis E, Verrou E, Anargyrou K, Tsionos K, Dimopoulos MA, Zervas K; Greek Myeloma Study Group. Terpos E, et al. Among authors: verrou e. Haematologica. 2009 Mar;94(3):372-9. doi: 10.3324/haematol.2008.000638. Haematologica. 2009. PMID: 19252175 Free PMC article. Clinical Trial.
Longitudinal cohort study of risk factors in cancer patients of bisphosphonate-related osteonecrosis of the jaw.
Vahtsevanos K, Kyrgidis A, Verrou E, Katodritou E, Triaridis S, Andreadis CG, Boukovinas I, Koloutsos GE, Teleioudis Z, Kitikidou K, Paraskevopoulos P, Zervas K, Antoniades K. Vahtsevanos K, et al. Among authors: verrou e. J Clin Oncol. 2009 Nov 10;27(32):5356-62. doi: 10.1200/JCO.2009.21.9584. Epub 2009 Oct 5. J Clin Oncol. 2009. PMID: 19805682
41 results